Jaypirca approved in China for CLL/SLL across all lines of therapy
LLY•Jaypirca (pirtobrutinib) was approved in China for a new indication in chronic lymphocytic leukemia and small lymphocytic lymphoma across all lines of therapy.
LLY•LLY•LLY•Jaypirca (pirtobrutinib) was approved in China for a new indication in chronic lymphocytic leukemia and small lymphocytic lymphoma across all lines of therapy.
Jaypirca (pirtobrutinib) was approved in China for a new indication in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) across all lines of therapy.
